ArticleJournal of cellular and molecular medicine2018
Baicalein inhibits cell growth and increases cisplatin sensitivity of A549 and H460 cells via miR-424-3p and targeting PTEN/PI3K/Akt pathway.
Article in Journal of cellular and molecular medicine, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 43 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
43 citing papers in PubMed, 1 synthesis or guideline pooled it.
- The effects of flavonoid baicalein on miRNA expressions in cancer: a systematic review.Naunyn-Schmiedeberg's archives of pharmacology · 2025Pooled it
- Research progress of MicroRNA in lung cancer.Discover oncology · 2026Review
- Identifying the potential anti-lung cancer targets of Baicalein using a network pharmacology approach.Scientific reports · 2026Article
- Bioactive Flavonoids fromDrug design, development and therapy · 2026Review
- Exploring the mechanisms of baicalein in lung adenocarcinoma: an integrative preliminary study with focused experimental assessment in A549 cells.Frontiers in oncology · 2026Article
- PEITC restores chemosensitivity in cisplatin-resistant non-small cell lung cancer by targeting c-Myc/miR-424-5p.Discover oncology · 2025Article
- Baicalein induces apoptosis by inhibiting the glutamine-mTOR metabolic pathway in lung cancer.Journal of advanced research · 2025Article
- Oxaliplatin-induced upregulation of exosomal miR-424-3p derived from human bone marrow mesenchymal stem cells attenuates progression of gastric cancer cells.Scientific reports · 2024Article
- The Role of the PTEN Tumor Suppressor Gene and Its Anti-Angiogenic Activity in Melanoma and Other Cancers.Molecules (Basel, Switzerland) · 2024Review
- Cisplatin-Based Combination Therapy for Enhanced Cancer Treatment.Current drug targets · 2024Review
- Role of miR-424 in the carcinogenesis.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2024Review
- Investigation of the activity of baicalein towards Zika virus.BMC complementary medicine and therapies · 2023Article
- Baicalein as Promising Anticancer Agent: A Comprehensive Analysis on Molecular Mechanisms and Therapeutic Perspectives.Cancers · 2023Review
- In Vitro Study of Cytostatic Activity of Baicalin, Baicalein, and Chlorophyllipt on HeLa-v Cell Line.Bulletin of experimental biology and medicine · 2023Article
- Advances in the role of microRNAs associated with the PI3K/AKT signaling pathway in lung cancer.Frontiers in oncology · 2023Review
- The Multifaceted Role of Baicalein in Cancer Management through Modulation of Cell Signalling Pathways.Molecules (Basel, Switzerland) · 2022Review
- Polyphenols as Lung Cancer Chemopreventive Agents by Targeting microRNAs.Molecules (Basel, Switzerland) · 2022Review
- Network pharmacology analysis of the mechanism of Huisheng oral liquid in the treatment of lung cancer.Translational cancer research · 2022Article
- Latest research progress on anticancer effect of baicalin and its aglycone baicalein.Archives of pharmacal research · 2022Review
- Regulation of Cell Signaling Pathways and Non-Coding RNAs by Baicalein in Different Cancers.International journal of molecular sciences · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Lung cancer is the leading cause of death in individuals with malignant disease. Non-small-cell lung cancer (NSCLC) is the most common type of lung cancer, and chemotherapy drugs such as cisplatin are the most widely used treatment for this disease. Baicalein is a purified flavonoid compound that has been reported to inhibit cancer cell growth and metastasis and increase sensitization to chemotherapeutic drugs via different pathways. Therefore, we assessed the effects of baicalein on the proliferation, apoptosis and cisplatin sensitivity in the NSCLC A549 and H460 cell lines and determined the pathways through which baicalein exerts its effects. Baicalein was slightly toxic to normal human bronchial NHBE cells but inhibited growth, induced apoptosis and increased cisplatin sensitivity in A549 and H460 cells. Baicalein down-regulated miR-424-3p, up-regulated PTEN expression and down-regulated expression of PI3K and p-Akt in A549 and H460 cells. Dual-luciferase reporter assay demonstrated that PTEN is a target gene of miR-424-3p, and overexpression of miR-424-3p or silencing of PTEN partially attenuated the effects of baicalein on A549 and H460 cells. Taken together, we concluded that baicalein inhibits cell growth and increases cisplatin sensitivity to A549 and H460 cells via down-regulation of miR-424-3p and targeting the PTEN/PI3K/Akt pathway.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.